

Mukul Minocha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11302425/publications.pdf>

Version: 2024-02-01

14
papers

460
citations

1040056

9
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

834
citing authors

#	ARTICLE	IF	CITATIONS
1	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 671-680.	8.1	126
2	Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. <i>International Journal of Pharmaceutics</i> , 2012, 434, 306-314.	5.2	74
3	Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. <i>International Journal of Pharmaceutics</i> , 2012, 436, 127-134.	5.2	60
4	Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 901, 85-92.	2.3	37
5	Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 179-190.	0.3	30
6	Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. <i>Drug Metabolism and Drug Interactions</i> , 2014, 29, 249-259.	0.3	27
7	Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. <i>Clinical Pharmacokinetics</i> , 2019, 58, 375-387.	3.5	25
8	Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1309-1321.	3.5	25
9	Effect of short term and chronic administration of <i>Sutherlandia frutescens</i> on pharmacokinetics of nevirapine in rats. <i>International Journal of Pharmaceutics</i> , 2011, 413, 44-50.	5.2	21
10	Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials. <i>Clinical Pharmacokinetics</i> , 2016, 55, 121-130.	3.5	9
11	Models of Variability and Circadian Rhythm in Heart Rate, Blood Pressure, and QT Interval for Healthy Subjects Who Received Placebo in Phase I Trials. <i>Clinical and Translational Science</i> , 2019, 12, 470-480.	3.1	8
12	Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1185-1198.	3.5	7
13	Drug Development and Potential Regulatory Paths for Insulin Biosimilars. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 14-19.	2.2	6
14	Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2020, 59, 335-347.	3.5	5